Disease Modulation Versus Modification: A Call for Revised Outcome Metrics in the Treatment of Thyroid Eye Disease
Authors:
- 25 January 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Ophthalmic Plastic & Reconstructive Surgery
- Vol. 40 (2) , 156-160
Abstract
Purpose: This perspective introduces the concepts of disease-modulating and -modifying therapy for thyroid eye disease and offers novel metrics for therapeutic outcomes. Methods: A focused literature review was performed. Results: Modulators are treatments that suppress disease symptoms whereas modifiers alter the natural history of a disease. Though many drugs are capable of exhibiting both effects, consideration of a drug’s primary effect is useful when considering therapeutic options. For thyroid eye disease, corticosteroids and teprotumumab are effective at modulating many signs and symptoms of the disease, particularly those related to soft tissue inflammation. Orbital radiotherapy and rituximab have demonstrated effectiveness at durably modifying the natural history of thyroid eye disease. Conclusions: Outcome metrics should reflect the unique therapeutic objectives associated with disease modulation and modification. This conceptual framework should guide treatment of thyroid eye disease.Keywords
This publication has 38 references indexed in Scilit:
- Orbital Radiation Therapy for Thyroid Eye DiseaseJournal of Neuro-Ophthalmology, 2012
- Validity and reliability of the TED-QOL: a new three-item questionnaire to assess quality of life in thyroid eye diseaseBritish Journal of Ophthalmology, 2011
- Rituximab for Thyroid Eye DiseaseOphthalmic Plastic & Reconstructive Surgery, 2010
- Immunopathogenesis of Thyroid Eye Disease: Emerging ParadigmsSurvey of Ophthalmology, 2010
- Rituximab Treatment of Patients with Severe, Corticosteroid-Resistant Thyroid-Associated OphthalmopathyOphthalmology, 2010
- VISA Classification for Graves OrbitopathyOphthalmic Plastic & Reconstructive Surgery, 2006
- Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves’ ophthalmopathyInternational Journal Of Clinical Practice, 2006
- Treatment of Acute Graves OrbitopathyOphthalmology, 1991
- CYCLOPHOSPHAMIDE, GOLD AND PENICILLAMINE—DISEASE-MODIFYING DRUGS IN RHEUMATOID ARTHRITIS—TAILORED DOSAGE AND ULTIMATE SUCCESSRheumatology, 1976
- Adrenal steroid therapy of severe infiltrative ophthalmopathy of Graves' diseaseThe American Journal of Medicine, 1963